{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:42:55Z","timestamp":1781214175026,"version":"3.54.1"},"reference-count":90,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":1546,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> Since the introduction of highly active antiretroviral therapy (HAART), AIDS has become a treatable disease. A steep decline in morbidity and mortality has been observed in most western countries. The HIV epidemic is now moving into middle\u2010aged populations which are already at increased risk for cardiovascular disease. Since the cardiovascular system is frequently affected in HIV infection, reflections on traditional cardiovascular risk factors is a pressing issue. Moreover, during the last few years, complex lipodystrophic body changes in association with metabolic abnormalities such as dyslipidemia and insulin resistance have become a common feature in HIV<jats:sup>+<\/jats:sup> patients on HAART. Although the precise mechanisms are not fully understood, early reports on myocardial infarctions and vascular changes have raised concern about the possibility of an epidemic of cardiovascular events among HAART patients within the next decade. Not only more data on lipid\u2010lowering drugs in the context of HAART, on switching strategies, and treatment interruptions, but also from intervention studies on traditional risk factors such as smoking, are urgently needed. In this review the key issues concerning cardiovascular aspects of HIV infection in the era of HAART and possible preventive strategies are discussed.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2001.tb03908.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T09:37:16Z","timestamp":1279877836000},"page":"130-144","source":"Crossref","is-referenced-by-count":17,"title":["Cardiology and AIDS\u2014HAART and the Consequences"],"prefix":"10.1111","volume":"946","author":[{"given":"CHRISTIAN","family":"HOFFMANN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HANS","family":"JAEGER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02504-6"},{"key":"e_1_2_14_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/8394"},{"key":"e_1_2_14_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402102"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402101"},{"key":"e_1_2_14_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199806010-00006"},{"key":"e_1_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0146-2806(90)90008-E"},{"key":"e_1_2_14_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90913-W"},{"key":"e_1_2_14_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(91)91013-D"},{"key":"e_1_2_14_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1998.14.1071"},{"key":"e_1_2_14_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a062583"},{"key":"e_1_2_14_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810153391601"},{"key":"e_1_2_14_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.5.602"},{"key":"e_1_2_14_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960210704"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.263.16.2149"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(00)00232-1"},{"key":"e_1_2_14_18_2","first-page":"1887","article-title":"Aortic endothelium in HIV\u20101 infection: chronic injury, activation, and increased leukocyte adherence","volume":"149","author":"Zietz C.","year":"1996","journal-title":"Am. J. Pathol."},{"key":"e_1_2_14_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-2516(06)80033-6"},{"key":"e_1_2_14_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-200002000-00008"},{"key":"e_1_2_14_21_2","first-page":"127","article-title":"Endothelial cell dysfunction in HIV infection","volume":"5","author":"Lafeuillade A.","year":"1992","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"e_1_2_14_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7136.953"},{"key":"e_1_2_14_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(00)80253-1"},{"key":"e_1_2_14_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890470411"},{"key":"e_1_2_14_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922299310160"},{"key":"e_1_2_14_26_2","first-page":"M8","article-title":"The emergence of triglycerides as a significant independent risk in coronary artery disease","author":"Assmann G.","year":"1998","journal-title":"Eur. Heart J."},{"key":"e_1_2_14_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90225-8"},{"key":"e_1_2_14_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/314048"},{"key":"e_1_2_14_29_2","first-page":"116","volume":"21","author":"Niaura R.","year":"1999","journal-title":"Smoking among HIV-positive persons. Ann. Behav. Med."},{"key":"e_1_2_14_30_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0002-9629(15)40512-9","article-title":"Absence of age\u2010related increase in systolic blood pressure in ambulatory patients with HIV infection","volume":"317","author":"Mattana J.","year":"1999","journal-title":"Am. J. Med. Sci."},{"key":"e_1_2_14_31_2","first-page":"835","article-title":"Cardiac side effects of anti\u2010HIV agents","volume":"93","author":"Monsuez J.J.","year":"2000","journal-title":"Arch. Mal. Coeur Vaiss."},{"key":"e_1_2_14_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00124-1"},{"key":"e_1_2_14_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2000.0672"},{"key":"e_1_2_14_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79053-X"},{"key":"e_1_2_14_35_2","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/S0140-6736(98)26026-0","article-title":"Vascular complications associated with use of protease inhibitors","volume":"351","author":"Behrens G.","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_14_36_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-7-199910050-00032"},{"key":"e_1_2_14_37_2","first-page":"2499","article-title":"Severe coronary artery disease in a young HIV\u2010infected man with no cardiovascular risk factor who was treated with indinavir","volume":"12","author":"Karmochkine M.","year":"1998","journal-title":"AIDS"},{"key":"e_1_2_14_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200012010-00021"},{"key":"e_1_2_14_39_2","first-page":"329","article-title":"Incidence of myocardial infarctions in HIV\u2010infected patients between 1983 and 1998: The Frankfurt HIV\u2010Cohort Study","volume":"5","author":"Rickerts V.","year":"2000","journal-title":"Eur. J. Med. Res."},{"key":"e_1_2_14_40_2","unstructured":"Juette A. B. Salzberger C. Franzen et al.1999. Increased morbidity from severe coronary heart disease in HIV\u2010patients receiving protease inhibitors. Presented at the 6thConference on Retroviruses and Opportunistic Infections Chicago IL USA. Abstract 656."},{"key":"e_1_2_14_41_2","unstructured":"Coplan P. A. Nikas A. Saah et al.1999. No association observed between indinavir therapy for HIV\/AIDS and myocardial infarction in 4 clinical trials with 2 825 subjects. Presented at the 6thConference on Retroviruses and Opportunistic Infections Chicago IL USA. Abstract 658."},{"key":"e_1_2_14_42_2","unstructured":"Lenormand\u2010Welckenaer C. M. Cazaubon V. Joly et al.2000. Carotid intima media thickness in protease inhibitor\u2010treated HIV\u20101 infected patients with hyperlipemia. Presented at the 40thInterscience Conference on Antimicrobial Agents and Chemotherapy Toronto Ont. Canada. Abstract 1298."},{"key":"e_1_2_14_43_2","unstructured":"Cheminot N. J. Gariepy G. Chironi et al.2000. Diagnosis and determinants of subclinical arterial disease in HIV1\u2010infected patients on HAART. Presented at the 7thConference on Retroviruses and Opportunistic Infections San Francisco CA USA. Abstract 31."},{"issue":"5","key":"e_1_2_14_44_2","first-page":"16","volume":"5","author":"Sosman J.","year":"2000","journal-title":"Use of HIV protease inhibitors is associated with endothelial dysfunction. Antiviral Ther."},{"key":"e_1_2_14_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200011100-00001"},{"key":"e_1_2_14_46_2","unstructured":"Depairon M. S. Chessex A. Telenti et al.2000. Noninvasive morphological analysis of carotid and femoral arteries in protease\u2010inhibitor\u2010treated HIV\u2010infected individuals. Presented at the 7thConference on Retroviruses and Opportunistic Infections San Francisco CA USA. Abstract 30."},{"key":"e_1_2_14_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02854-3"},{"key":"e_1_2_14_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)08468-2"},{"key":"e_1_2_14_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03391-1"},{"key":"e_1_2_14_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)06102-4"},{"issue":"5","key":"e_1_2_14_51_2","first-page":"5","volume":"5","author":"Walker U.A.","year":"2000","journal-title":"Decrease of mitochondrial DNA content in adipose tissue of HIV-1-infected patients treated with NRTIs. Antiviral Ther."},{"issue":"5","key":"e_1_2_14_52_2","first-page":"4","volume":"5","author":"Caron M.","year":"2000","journal-title":"The HIV-protease inhibitor indinavir impairs adipocyte differentiation and induces insulin resistance by probably altering ADD 1\/SREBP-1 maturation. Antiviral Ther."},{"issue":"5","key":"e_1_2_14_53_2","first-page":"4","volume":"5","author":"Parker R.A.","year":"2000","journal-title":"Effects of nucleoside reverse transcriptase inhibitors and HIV protease inhibitors on adipogenesis and adipocyte metabolism. Antiviral Ther."},{"issue":"5","key":"e_1_2_14_54_2","first-page":"12","volume":"5","author":"Liang J.","year":"2000","journal-title":"HIV protease inhibitors increase secretion of apolipoproteins from hepatoma cells by preventing proteasomal degradation. Antiviral Ther."},{"issue":"5","key":"e_1_2_14_55_2","first-page":"13","volume":"5","author":"Distler O.","year":"2000","journal-title":"Direct effects of protease inhibitors on lipid metabolism in cultured mammalian cells. Antiviral Ther."},{"key":"e_1_2_14_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200011100-00007"},{"key":"e_1_2_14_57_2","unstructured":"Mauss S. E. Wolf M. Corzillius et al.2000. Prevalence and risk factors for the HIV\u2010associated lipodystrophy syndrome (HALS) in patients being 3 years on ART. Presented at the 40thInterscience Conference on Antimicrobial Agents and Chemotherapy Toronto Ont. Canada. Abstract 1287."},{"key":"e_1_2_14_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007070-00002"},{"key":"e_1_2_14_59_2","doi-asserted-by":"publisher","DOI":"10.1086\/317541"},{"key":"e_1_2_14_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200008180-00020"},{"key":"e_1_2_14_61_2","doi-asserted-by":"publisher","DOI":"10.1086\/313995"},{"key":"e_1_2_14_62_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-10-199811150-00022"},{"key":"e_1_2_14_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199907090-00001"},{"issue":"5","key":"e_1_2_14_64_2","first-page":"7","volume":"5","author":"Germinario R.J.","year":"2000","journal-title":"The effects of a variety of protease inhibitors on insulin binding insulin-mediated sugar transport and cell toxicity in insulin target and non-target cell cultures. Antiviral Ther."},{"issue":"5","key":"e_1_2_14_65_2","first-page":"8","volume":"5","author":"Noor M.","year":"2000","journal-title":"Metabolic effects of indinavir in healthy HIV-seronegative subjects. Antiviral Ther."},{"key":"e_1_2_14_66_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200012010-00004"},{"issue":"5","key":"e_1_2_14_67_2","first-page":"15","volume":"5","author":"Hadigan C.","year":"2000","journal-title":"Increased tPA antigen levels in the HIV lipodystrophy syndrome are reduced to response to metformin. Antiviral Ther."},{"key":"e_1_2_14_68_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.4.472"},{"key":"e_1_2_14_69_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.7.700"},{"key":"e_1_2_14_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02560501"},{"key":"e_1_2_14_71_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462001916236"},{"key":"e_1_2_14_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)00022-1"},{"key":"e_1_2_14_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1994.tb02185.x"},{"key":"e_1_2_14_74_2","doi-asserted-by":"publisher","DOI":"10.1086\/317429"},{"key":"e_1_2_14_75_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.3.1333"},{"key":"e_1_2_14_76_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.7.727.35179"},{"key":"e_1_2_14_77_2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444. patients with coronary heart disease","volume":"344","author":"Scandinavian Simavastatin Survival Study (4 S).","year":"1994","journal-title":"Lancet."},{"key":"e_1_2_14_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)04292-4"},{"key":"e_1_2_14_79_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199905070-00023"},{"key":"e_1_2_14_80_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199907300-00030"},{"key":"e_1_2_14_81_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.13.1066.35033"},{"key":"e_1_2_14_82_2","unstructured":"Fichtenbaum C. J. Gerber & S. Rosenkranz. 2000. Pharmacokinetic interactions between protease inhibitors and selected HMG\u2010CoA reductase inhibitors. Presented at the 7thConference on Retroviruses and Opportunistic Infections San Francisco CA USA. Abstract LB6."},{"key":"e_1_2_14_83_2","unstructured":"Goebel F. & R.K. Walli for the CNA30017 Study Team. 2000. A novel use of abacavir to simplify therapy in PI experienced patients successfully treated with HAART: CNA30017. Presented at the 7thConference on Retroviruses and Opportunistic Infections San Francisco CA USA. Abstract 51."},{"key":"e_1_2_14_84_2","unstructured":"Carr A. & D.A. Cooper. 2000. A randomized multicenter study of protease inhibitor substitution in aviremic patients with antiretroviral lipodystrophy syndrome. Presented at the 7thConference on Retroviruses and Opportunistic Infections San Francisco CA USA. Abstract 205."},{"key":"e_1_2_14_85_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200005050-00006"},{"key":"e_1_2_14_86_2","unstructured":"Ruiz L. E. Negredo P. Domingo et al.2000. Clinical virological and immunological benefit of switching the protease inhibitor by nevirapine in HAART experienced patients suffering lipodystrophy (LD): 36\u2010week follow\u2010up. Presented at the 7thConference on Retroviruses and Opportunistic Infections San Francisco CA USA. Abstract 206."},{"key":"e_1_2_14_87_2","unstructured":"Hoffmann C. E. Jaegel\u2010Guedes E. Wolf et al.2000. PI to Efavirenz (EFV) switch effect on lipids in HIV\u2010positive patients. Presented at the XIIIth International AIDS Conference Durban South Africa. Abstract WePeB4185."},{"key":"e_1_2_14_88_2","unstructured":"Hoffmann C. E. Wolf S. Mueller et al.2000. Drug holidays in HIV+patients\u2014clinical issues. Presented at the Fifth International Congress on Drug Therapy in HIV Infection Glasgow Scotland. Abstract 68."},{"key":"e_1_2_14_89_2","unstructured":"Egger M. 2000. Cardiovascular epidemiology in the context of HIV disease. Presented at the 40thInterscience Conference on Antimicrobial Agents and Chemotherapy Toronto Ont. Canada. Abstract 1374."},{"key":"e_1_2_14_90_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-12-199706150-00003"},{"key":"e_1_2_14_91_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.23.2220"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2001.tb03908.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2001.tb03908.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1749-6632.2001.tb03908.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2001.tb03908.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T09:30:07Z","timestamp":1694338207000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2001.tb03908.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1111\/j.1749-6632.2001.tb03908.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb03908.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]}}}